The evaluation for safety and efficacy of combination therapy of adoptive immune-cell therapy with chemoradiotherapy for locally advanced esophageal cancer
Not Applicable
Recruiting
- Conditions
- ocally advanced esophageal cancer (HLA type A2/A24)
- Registration Number
- JPRN-UMIN000014099
- Lead Sponsor
- Gunma University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Patient with interstitial pneumonia (2)Patient with active autoimmune disease (3)Patient with active heart disease (4)Patient with uncontrolable infectious diseases (5)Patient with serious drug allergy (6)Patient with continuous use of systemic administration of steroids (7)Patient in pregnancy (8)Patient positive for HIV or HTLV-1 (9)Patients who are inadequate to enter this study due to the other reasons by physician's judgments
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method